Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00106288 · ClinicalTrials.gov registry record · Phase 3
Micafungin Versus AmBisome in Invasive Candidiasis and Candidemia
A Phase 3 study, sponsored by Astellas Pharma.
- Completed
- Registry status
- Phase 3
- Development phase
- 637
- Enrollment target
NCT00106288: Completed Phase 3 study, sponsored by Astellas Pharma.
NCT00106288 is a Phase 3 study that has completed, run by Astellas Pharma. The registered enrollment target is 637 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (17% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00106288, a Phase 3 study, has completed, sponsored by Astellas Pharma.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 637 participants
- Enrollment target
Study Summary
The purpose of this study is to determine the efficacy and safety of micafungin (FK463) versus liposomal amphotericin B (AmBisome) in treating neutropenic and non-neutropenic patients with confirmed invasive candidiasis or candidemia. Enrollment will include adult and pediatric patients.
Interventions
- DRUG Micafungin
- DRUG Liposomal Amphotericin B
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 637 participants |
| Start Date | 2003-01 |
| Est. Completion | 2005-12 |
| Phase | Phase 3 |
What the finished NCT00106288 record still lists
NCT00106288 is an interventional study that assigns participants to a tested intervention. The registered 637 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (17% lower).
The record links to 0 conditions, and to 2 interventions - of which Micafungin is the first listed.
NCT00106288 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00106288 about?
NCT00106288 is a clinical study titled "Micafungin Versus AmBisome in Invasive Candidiasis and Candidemia". The purpose of this study is to determine the efficacy and safety of micafungin (FK463) versus liposomal amphotericin B (AmBisome) in treating neutropenic and non-neutropenic patients with confirmed invasive candidiasis or candidemia. Enrollment will include adult and pediatric patients.
What is the current status of trial NCT00106288?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 637 participants. The study started on 2003-01. Estimated completion is 2005-12.
What interventions are being tested in trial NCT00106288?
The interventions under investigation include: Micafungin (DRUG), Liposomal Amphotericin B (DRUG).
Who is sponsoring clinical trial NCT00106288?
This trial is sponsored by Astellas Pharma, which has 165 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00106288's enrollment target sits among peer trials
637 579th of 2000 higher than 1,422 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03821129 · 636 participants · NA
GORE® CARDIOFORM Septal Occluder and Antiplatelet Medical Management for Reduction of Recurrent Stroke in Patients With Patent Foramen Ovale (PFO): the REDUCE Post Approval Study
- NCT03478826 · 635 participants
Creation of a Biospecimen Repository From Patients With Interstitial Lung Diseases (ILD)
- NCT04339699 · 640 participants · NA
NobleStitch EL STITCH Trial is a PFO Comparative Trial
- NCT04979338 · 640 participants · Phase 3
Development of Effective, Opioid Sparing Techniques for Peri-operative Pain Management of Transgender Patients Undergoing Gender Affirming Surgeries
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia